Supplementary Material

Tislelizumab + Chemotherapy in Gastric Cancer: Long-Term RATIONALE-305 Randomized Trial Follow-up

Marcia Cruz-Correa · Do-Youn Oh · Ken Kato · Josep Tabernero · Yuxian Bai · Jianhua Shi · Keun-Wook Lee · Hidekazu Hirano · David Spigel · Lucjan Wyrwicz · Roberto Pazo Cid · Antonio Cubillo Gracián · Yaling Xu · Tao Sheng · Silu Yang · Rui-Hua Xu · Markus Moehler

M. Cruz-Correa, School of Medicine, University of Puerto Rico, and Pan American Center for Oncology Trials, San Juan, Puerto Rico

D.-Y. Oh, Department of Hemato-Oncology, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea

K. Kato, Department of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan

J. Tabernero, Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain

Y. Bai, Department of Gastrointestinal Oncology, Harbin Medical University Cancer Hospital, Harbin, China

J. Shi, Department II of Medical Oncology, Linyi Cancer Hospital, Harbin, China

K.-W. Lee, Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Korea

H. Hirano, Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan

D. Spigel, Department of Oncology, Tennessee Oncology, Nashville, TN, USA

L. Wyrwicz, Department of Oncology and Radiotherapy, Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie – Państwowy Instytut Badawczy, Warsaw, Poland

R. Pazo Cid, Medical Oncology Department, Hospital Universitario Miguel Servet, Zaragoza, Spain

A. Cubillo Gracián, Medical Oncology Department, Hospital Universitario Hm Sanchinarro, Madrid, Spain

Y. Xu, Clinical Development, BeOne (Shanghai) Co., Ltd., Shanghai, China

T. Sheng, *Biostatistics, BeOne Medicines USA, Inc., Emeryville, CA, USA

S. Yang, Clinical Biomarkers, BeOne (Beijing) Co., Ltd., Beijing, China

R.-H. Xu, Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China

M. Moehler, Department of Medicine, University Medical Center of Johannes Gutenberg University, Mainz, Germany

*At time of study

Corresponding Author: Markus Moehler
E-mail: markus.moehler@unimedizin-mainz.de

SUPPLEMENTARY METHODS

Study Design

Eligible patients were randomized (1:1) to receive either tislelizumab 200 mg or matching placebo intravenously every 3 weeks, in combination with investigator-chosen chemotherapy every 3 weeks (capecitabine 1000 mg/m² twice daily on days 1–14 and oxaliplatin 130 mg/m² on day 1 or 5-fluorouracil 800 mg/m² on days 1–5 and cisplatin 80 mg/m² on day 1) for up to six cycles, followed by continued treatment with either tislelizumab or placebo, with optional maintenance capecitabine. Randomization was stratified according to region [China (including Taiwan) vs. Japan and South Korea vs. Europe and North America], programmed death ligand 1 (PD-L1) expression [PD-L1 Tumor Area Positivity (TAP) score $\geqslant$ 5% or < 5%], peritoneal metastases (yes vs. no), and investigator's choice of chemotherapy (oxaliplatin and capecitabine vs. cisplatin and 5-fluorouracil). Treatment continued until disease progression, unacceptable toxicity, or investigator's decision after 2 years of study treatment. Crossover between the treatment arms or between chemotherapy regimens was prohibited.

PD-L1 expression was assessed prospectively by central laboratory using the TAP score, defined as the total percentage of tumor area (tumor and any desmoplastic stroma) covered by tumor cells with PD-L1 membrane staining (any intensity) and tumor-associated immune cells with PD-L1 staining (any intensity), visually estimated by pathologists using an investigational use–only version of the VENTANA PD-L1 (SP263) Assay (Roche Diagnostics, Indianapolis, IN, USA) [1,2]. In addition, for exploratory purposes, pathologists in the central laboratory scored the same stained samples according to combined positive score (CPS). CPS is defined as the number of PD-L1–expressing tumor cells, lymphocytes, and macrophages divided by the total number of viable tumor cells, multiplied by 100 [2,3].

Patient-Reported Outcomes

Patient-reported outcomes (PROs) were assessed in all randomized patients who completed the PRO questionnaires, the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire – Core 30 (QLQ-C30) and its gastric cancer module (QLQ-STO22) at baseline and at least once post baseline. For each key PRO endpoint (ie, the most disease- and treatment-relevant scales), the time to deterioration (defined as time to first onset of a > 10-point change [4] in the worsening direction from baseline with confirmation by a subsequent worsening) and a mixed model for repeated measures from baseline to key clinical cycles of 4 and 6 were measured.

REFERENCES

1. Liu C, Fang F, Kong Y, ElGabry EA. Tumor Area Positivity (TAP) score of programmed death-ligand 1 (PD-L1): a novel visual estimation method for combined tumor cell and immune cell scoring. Diagn Pathol. 2023;18(1):48.

2. Qiu MZ, Oh DY, Kato K, et al. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial. BMJ. 2024;385:e078876.

3. Paintal AS, Brockstein BE. PD-L1 CPS scoring accuracy in small biopsies and aspirate cell blocks from patients with head and neck squamous cell carcinoma. Head Neck Pathol. 2020;14(3):657-65.

4. Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol. 1998;16(1):139-44.

List of ethics committees by site number

Site No.	Principal investigator name	Name/Address of ethics committee	Approval number
001028	David Spigel (May 25, 2021 to January 3, 2024, site closure) Johanna Bendell (March 5, 2019, to May 25, 2021)	IntegReview Ethical Review Board (Advarra), 3815 S. Capital of Texas Highway, Austin, TX 78704	N/A - IRB does not issue an approval number
001119	Efrat Dotan (October 13, 2021, to August 13, 2024, site closure) Rishi Jain (March 12, 2021, to October 13, 2021) Crystal Denlinger (July 24, 2019, to March 12, 2021)	Western Institutional Review Board, 1019 39th Avenue SE, Puyallup, WA 98374	20182456
001129	John Hays	Western Institutional Review Board, 1019 39th Avenue SE, Puyallup, WA 98374	20182456
001165	Arturo Loaiza-Bonilla (August 21, 2021, to site closure) Eyal Meiri (June 7, 2019, to May13, 2021) Herbert Duvivier	Copernicus Group IRB, 5000 CentreGreen Way, Cary, NC 27513 (part of WIRB)	20182456

Site No.	Principal investigator name	Name/Address of ethics committee	Approval number
	(May 13, 2021, to August 21, 2021)		
001170	Terrance Cescon	Reading Hospital Institutional Review Board, 420 S. 5th Avenue, West Reading, PA 19611	N/A - IRB does not issue an approval number
001175	Edward Kim (January 11, 2021, to site closure) May Cho (July 17, 2019, to January 10, 2021)	Institutional Review Board, University of California Davis, CTSC Building, Sacramento, CA 95817	N/A - IRB does not issue an approval number
007013	Nadezhda Kovalenko	Local Ethics Committee at the State Budgetary Healthcare Institution Volgograd Regional Clinical Oncology Dispensary 400138, 78 Zemlyachki St., Volgograd, Russia	1/124 dd 04Oct2019
007020	Yana Chapko (December 8, 2022, to site closure) Lyudmila Lebedeva (February 16, 2022, to December 7, 2022) Marina Nechaeva (May 31, 2019, to February 15, 2022)	Ministry of Healthcare of the Russian Federation Ethic Committee at Arkhangelsk Clinical Oncology Dispensary, 145 Bldg. 1 Obvodniy Kanal Ave., Arkhangelsk 163045, Russia	760 dd 04Feb2019

Site No.	Principal investigator name	Name/Address of ethics committee	Approval number
007026	Anastasia Zimina (June 6, 2022, to site closure) Mikhail Vladimirovich Dvorkin (June 6, 2019, to June 6, 2022)	Ethics Committee at the Budgetary Healthcare Institution of the Omsk Region 'Clinical Oncology Dispensary,' 9/1 Zavertyaeva Str., Omsk 644013, Russia	12 dd 04Apr2019
007027	Evgeniy Gotovkin	Ethics Committee at RBIH "Ivanovo Regional Oncological Dispensary," 153040, 5 Lubimova St., Ivanovo, Russia	02/19 dd 27Feb2019
007028	Mikhail Kopp	Ethics Committee at the Private Institution of Higher Education Organization Reaviz Medical University / 443030, 100 Chkalov St., Samara, Russia	1 dd 17Jan2019
007029	Fedor Vladimirovich Moiseenko	Local Ethics Committee of State Budgetary Healthcare Institution “Saint-Petersburg Clinical Research and Practical Center for specialized medical care (oncology),” lit A, 68A Leningradskaya str., pos. Pesochniy, Saint Petersburg 197758, Russia	24 dd 25Mar2019
007030	Elena Poddubskaya	Ethics Committee at VitaMed LLC / 121309, 10 Seslavinskaya St., Moscow, Russia	NA - IRB does not issue an approval number

Site No.	Principal investigator name	Name/Address of ethics committee	Approval number
007032	Nikolay Kislov	The Independent Interdisciplinary Committee on Ethical Review of Clinical Studies / 125468 51, Leningradskiy prospect, Moscow, Russia	01 dd 18Jan2019
007034	Sergey Dvoretskiy	Local Ethics Committee of Federal State Budgetary Educational Institution of Higher Education “First Saint-Petersburg state medical university named after academician I. P. Pavlov,” blud. 46, 6-8 Lva Tolstogo str, Saint Petersburg 197022, Russia	225 dd 25Dec2019
007039	Vadim Kozlov	Local Ethics Committee at State Budgetary Institution of Healthcare of the Novosibirsk Region “Novosibirsk Regional Clinical Oncological Dispensary,” 2 Plakhotnogo str., Novosibirsk 630108, Russia	2312/49 dd23Dec2019
007058	Sergey Orlov	Local Ethics Committee of Federal State Budgetary Educational Institution of Higher Education “First Saint-Petersburg state medical university named after academician I. P. Pavlov,” blud. 46, 6-8 Lva Tolstogo str, Saint Petersburg 197022, Russia	225 dd 25Dec2019

Site No.	Principal investigator name	Name/Address of ethics committee	Approval number
033031	Denis Smith	ILE DE FRANCE III - ETHICS COMMITTEE, Hôpital Tarnier-Cochin [Tarnier-Cochin Hospital], 89 rue d'Assas 75006 Paris France	3690-I dd 23Jul2019
033038	Almotlak, Hamadi	ILE DE FRANCE III - ETHICS COMMITTEE, Hôpital Tarnier-Cochin [Tarnier-Cochin Hospital], 89 rue d'Assas 75006 Paris France	3690-I dd 23Jul2019
033044	Ghiringhelli, Francois	ILE DE FRANCE III - ETHICS COMMITTEE, Hôpital Tarnier-Cochin [Tarnier-Cochin Hospital], 89 rue d'Assas 75006 Paris France	3690-I dd 23Jul2019
033065	Evesque, Ludovic	ILE DE FRANCE III - ETHICS COMMITTEE, Hôpital Tarnier-Cochin [Tarnier-Cochin Hospital], 89 rue d'Assas 75006 Paris France	3690-I dd 23Jul2019
033070	Dahan, Laetitia	ILE DE FRANCE III - ETHICS COMMITTEE, Hôpital Tarnier-Cochin [Tarnier-Cochin Hospital], 89 rue d'Assas 75006 Paris France	3690-I dd 23Jul2019
033074	Dahan, Laetitia	ILE DE FRANCE III - ETHICS COMMITTEE, Hôpital Tarnier-Cochin [Tarnier-Cochin Hospital], 89 rue d'Assas 75006 Paris France	3690-I dd 23Jul2019

Site No.	Principal investigator name	Name/Address of ethics committee	Approval number
034003	Christophe Borg (October 1, 2021, to site closure) Stefano Kim (February 27, 2020, to September 30, 2021)	ILE DE FRANCE III - ETHICS COMMITTEE, Hôpital Tarnier-Cochin [Tarnier-Cochin Hospital], 89 rue d'Assas 75006 Paris France	01/2019 dd 09Jan2019
034006	Ana Ruiz Casado	Comité de Ética de la Investigación con Medicamentos Hospital General Universitario Gregorio Marañón, C / Dr. Esquerdo 46, Pabellón de Gobierno, Primera Planta, 28007 Madrid	01/2019 dd 09Jan2019
034017	Aitana Calvo Ferrandiz (January 22, 2022, to site closure) Montserrat Blanco Codesido (May 30, 2019, to January 22, 2022)	Comité de Ética de la Investigación con Medicamentos Hospital General Universitario Gregorio Marañón, C/ Dr. Esquerdo 46, Pabellón de Gobierno, Primera Planta, 28007 Madrid	01/2019 dd 09Jan2019
034018	Roberto Pazo Cid	Comité de Ética de la Investigación con Medicamentos Hospital General Universitario Gregorio Marañón, C / Dr. Esquerdo 46, Pabellón de Gobierno, Primera Planta, 28007 Madrid	01/2019 dd 09Jan2019

Site No.	Principal investigator name	Name/Address of ethics committee	Approval number
034021	Antonio Cubillo Gracian	Comité de Ética de la Investigación con Medicamentos Hospital General Universitario Gregorio Marañón, C / Dr. Esquerdo 46, Pabellón de Gobierno, Primera Planta, 28007 Madrid	01/2019 dd 09Jan2019
034026	Inmaculada Ales Diaz	Comité de Ética de la Investigación con Medicamentos Hospital General Universitario Gregorio Marañón, C / Dr. Esquerdo 46, Pabellón de Gobierno, Primera Planta, 28007 Madrid	01/2019 dd 09Jan2019
034027	Maria Luisa Limon Miron	Comité de Ética de la Investigación con Medicamentos Hospital General Universitario Gregorio Marañón, C / Dr. Esquerdo 46, Pabellón de Gobierno, Primera Planta, 28007 Madrid	01/2019 dd 09Jan2019
034030	Ana Belen Custodio Carretero	Comité de Ética de la Investigación con Medicamentos Hospital General Universitario Gregorio Marañón, C / Dr. Esquerdo 46, Pabellón de Gobierno, Primera Planta, 28007 Madrid	01/2019 dd 09Jan2019

Site No.	Principal investigator name	Name/Address of ethics committee	Approval number
034033	Tamara Sauri (November 15, 2021, to site closure) Francis Esposito (April 27, 2021, to November 15, 2021) Tamara Sauri (May 13, 2019, to April 27, 2021)	Comité de Ética de la Investigación con Medicamentos Hospital General Universitario Gregorio Marañón, C / Dr. Esquerdo 46, Pabellón de Gobierno, Primera Planta, 28007 Madrid	01/2019 dd 09Jan2019
034049	Tania Fleita Kanonnikoff	Comité de Ética de la Investigación con Medicamentos Hospital General Universitario Gregorio Marañón, C / Dr. Esquerdo 46, Pabellón de Gobierno, Primera Planta, 28007 Madrid	01/2019 dd 09Jan2019
034050	Borja Lopez De San Vicente Hernandez	Comité de Ética de la Investigación con Medicamentos Hospital General Universitario Gregorio Marañón, C / Dr. Esquerdo 46, Pabellón de Gobierno, Primera Planta, 28007 Madrid	01/2019 dd 09Jan2019
034051	Javier Gallego Plazas	Comité de Ética de la Investigación con Medicamentos Hospital General Universitario Gregorio Marañón, C / Dr. Esquerdo 46,	01/2019 dd 09Jan2019

Site No.	Principal investigator name	Name/Address of ethics committee	Approval number
		Pabellón de Gobierno, Primera Planta, 28007 Madrid	
039001	Mario Airoldi Paolo Pochettino	Comitato Etico Interaziendale AOU Cittá de la Salute e della Scienza di Torino Corso Bramante 88, Torino, Italy	CS2/1427 dd 17Oct2019
039008	Andrea Ardizzoni	COMITATO ETICO INDIPENDENTE DI AREA VASTA EMILIA CENTRO Via Albertoni 15, Bologna	158/2019/Farm/AOUB dd 20Mar2019
039018	Evaristo Maiello	Sezione del Comitato Etico IRCCS Istituto Tumori Giovanni Paolo II di Bari presso la Fondazione Casa Sollievo della Sofferenza di San Giovanni Rotondo (FG) Viale Cappuccini – 71013 San Giovanni Rotondo (FG)	07/2019 dd 28Jan2019
039032	Lorenzo Fornaro	COMITATO ETICO REGIONE TOSCANA - AREA VASTA NORD OVEST Via Roma 67, Pisa	14269_FORNARO dd 16May2019
039054	Silvia Stragliotto	Comitato Etico per la Sperimentazione Clinica dell'IRCCS (Istituto di Ricovero e Cura a Carattere Scientifico) ISTITUTO ONCOLOGICO VENETO VIA ANTENORE, 3, Padova	2019/05 dd 28Jan2019

Site No.	Principal investigator name	Name/Address of ethics committee	Approval number
039056	Rossana Berardi	Comitato Etico Regionale delle Marche Via Conca 71, Torrette di Ancona	2019 127 dd 11Apr2019
039057	Rossana Casaretti	Comitato Etico IRCCS Pascale, Napoli	93/18 dd 16Jan2019
039059	Mario Roselli	Comitato Etico IRCCS Pascale, Napoli	1/19 dd 23Jan2019
044010	Elisa Fontana (September 30, 2022, to site closure) Hendrik-Tobias Arkenau (October 24, 2019, to September 29, 2022)	East of England - Cambridge East Research Ethics Committee, The Old Chapel, Royal Standard Place, Nottingham, NG1 6FS, UK	19/EE/0189 dd 23Jul2019
044061	Carys Angharad Morgan	East of England - Cambridge East Research Ethics Committee, The Old Chapel, Royal Standard Place, Nottingham, NG1 6FS, UK	19/EE/0189 dd 23Jul2019
048020	Jacek Jassem	NIEZALEŻNA KOMISJA BIOETYCZNA DO SPRAW BADAŃ NAUKOWYCH, PRZY GDAŃSKIM UNIWERSYTECIE MEDYCZNYM, 80-210 Gdańsk, ul. M. Skłodowskiej-Curie 3a Poland	NKBBN/598/2018 dd 06Dec2018
048023	Lucjan Wyrwicz	NIEZALEŻNA KOMISJA BIOETYCZNA DO SPRAW BADAŃ NAUKOWYCH, PRZY	NKBBN/598/2018 dd 06Dec2018

Site No.	Principal investigator name	Name/Address of ethics committee	Approval number
		GDAŃSKIM UNIWERSYTECIE MEDYCZNYM, 80-210 Gdańsk, ul. M. Skłodowskiej-Curie 3a Poland	
048025	Justyna Borucka	NIEZALEŻNA KOMISJA BIOETYCZNA DO SPRAW BADAŃ NAUKOWYCH, PRZY GDAŃSKIM UNIWERSYTECIE MEDYCZNYM, 80-210 Gdańsk, ul. M. Skłodowskiej-Curie 3a Poland	NKBBN/598/2018 dd 06Dec2018
048026	Malgorzata Ulanska	NIEZALEŻNA KOMISJA BIOETYCZNA DO SPRAW BADAŃ NAUKOWYCH, PRZY GDAŃSKIM UNIWERSYTECIE MEDYCZNYM, 80-210 Gdańsk, ul. M. Skłodowskiej-Curie 3a Poland	NKBBN/598/2018 dd 06Dec2018
081001	Taroh Satoh	Osaka University Hospital IRB, Yamadaoka 2-15, Suita-shi, Osaka-Fu,Japan, 565-0871	190040-B Approval date-24Oct2019
081003	Hiroki Hara	Saitama Cancer Center IRB, Ina-machi Oaza Komuro 780, Kitaadachi-gun, Saitama-Ken, Japan, 362-0806	AA019-06 Approval date-28May2019
081004	Keiko Minashi	Chiba Cancer Center IRB/Chuo-ku Nitona-cho 666-2, Chiba-shi, Chiba-Ken, Japan, 260-8717	201911 Approval date-21Aug2019

Site No.	Principal investigator name	Name/Address of ethics committee	Approval number
081015	Hidekazu Hirano (July 2020 to site closure) Ken Kato (August 2019 to July 2020)	National Cancer Center Hospital IRB, Tsukiji 5-1-1, Chuo-ku, Tokyo-To, Japan, 104-0045	T4712 Approval date-03Sep2019
081016	Takashi Oshima	Kanagawa Cancer Center IRB, Asahi-ku Nakao 2-3-2, Yokohama-shi, Kanagawa-Ken, Japan, 241-8515	治 320 Approval date-27Nov2019
081018	Kazuhiko Yamada	Center Hospital of the National Center for Global Health and Medicine IRB/Toyama 1-21-1, Shinjuku-ku, Tokyo-To, Japan, 162-8655	A-261-19a Approval date-22Apr2019
081019	Yoshito Komatsu	Hokkaido University Hospital IRB, Kita-ku Kita 14jo Nishi 5, Sapporo-shi, Hokkaido, Japan, 060-8648	520 Approval date-16Jul2019
081030	Taito Esaki	NHO Kyushu Cancer Center IRB, Minami-ku Notame 3-1-1, Fukuoka-shi, Fukuoka-Ken, Japan, 811-1395	520 Approval date-20Nov2019
081032	Tomohiro Nishina	NHO Shikoku Cancer Center IRB, Minamiumemoto-machi Ko 160, Matsuyama-shi, Ehime-Ken, Japan, 791-0280	2019-14 Approval date-05Sep2019
081033	Akihito Tsuji	Kagawa University Hospital IRB, Miki-cho Ikenobe 1750-1, Kita-gun, Kagawa-Ken, Japan, 761-0793	N/A - IRB does not issue an approval number.

Site No.	Principal investigator name	Name/Address of ethics committee	Approval number
			Approval date-23Apr2019
081048	Kensei Yamaguchi	Cancer Institute Hospital of JFCR IRB, Ariake 3-8-31, Koto-ku, Tokyo-To, Japan, 135-8550	2019-0008 Approval date-23May2019
081049	Satoshi Otsu (November 2021 to site closure) Shuichi Hironaka (May 2019 to November 2021)	Oita University Hospital IRB, Hasama-machi Idaigaoka 1-1, Yufu-shi, Oita-Ken, Japan, 879-5593	A19-001 Approval date-24May2019
081050	Tetsuya Hamaguchi	Saitama Medical University International Medical Center IRB, Yamane 1397-1, Hidaka-shi, Saitama-Ken, Japan, 350-1298	No.266 Approval date-26Aug2020
081056	Toru Masuzawa (March 2021 to site closure) Atsushi Takeno (September 2020 to March 2021)	JOHAS Kansai Rosai Hospital IRB, Inabaso 3-1-69, Amagasaki-shi, Hyogo-Ken, Japan, 660-8511	20A047a Approval date-29Sep2020
081057	Hiroshi Tsukuda	Tokushukai Group IRB, Koji-machi 1-8-7, Chiyoda-ku, Tokyo-To, Japan, 102-0083	070-19-02 Approval date-03Sep2019

Site No.	Principal investigator name	Name/Address of ethics committee	Approval number
081058	Hiroya Takeuchi (September 2019 to site closure) Yasuhide Yamada (April 2019 to September 2019)	Hamamatsu University School of Medicine, University Hospital IRB, Higashi-ku Handayama 1-20-1, Hamamatsu-shi, Shizuoka-Ken, Japan, 431-3192	694 Approval date-09Apr2019
081075	Yoshio Nagahisa	Kurashiki Central Hospital IRB, Miwa 1-1-1, Kurashiki-shi, Okayama-Ken, Japan, 710-8602	692 Approval date-16Sep2020
081076	Kunihiro Tsuji	Ishikawa Prefectural Central Hospital IRB, Kuratsukihigashi 2-1, Kanazawa-shi, Ishikawa-Ken, Japan, 920-8530	N/A - IRB does not issue an approval number. Approval date-14Apr2020
081077	Hisashi Hosaka	Gunma Prefectural Cancer Center IRB, Takahayashinishi-cho 617-1, Ota-shi, Gunma-Ken, Japan, 373-8550	R2-7 Approval date-25Sep2020
081078	Motohiro Hirao (March 2021 to site closure) Kazuhiro Nishikawa (August 2020 to March 2021)	NHO Osaka National Hospital IRB, Chuo-ku Hoenzaka 2-1-14, Osaka-shi, Osaka-Fu, Japan, 540-0006	2020-0008 Approval date-24Sep2020
081079	Toshiyoshi Fujiwara	Okayama University Hospital IRB, Kita-ku Shikata-cho 2-5-1, Okayama-shi, Okayama-Ken, Japan, 700-8558	20200602 Approval date-28Aug2020

Site No.	Principal investigator name	Name/Address of ethics committee	Approval number
081080	Yu Oyama	Tesshokai Kameda General Hospital IRB, Higashi-cho 929, Kamogawa-shi, Chiba-Ken, Japan, 296-8602	N/A - IRB does not issue an approval number. Approval date-23Sep2020
081082	Yuji Ishibashi (April 2021 to site closure) Kazuhiro Imamura (July 2020 to March 2021)	Tokyo Metropolitan Tama Medical Center IRB, Musashidai 2-8-29, Fuchu-shi, Tokyo-To, Japan, 183-8524	1052 Approval date-31Jul2020
082001	Sun Young Rha (July 29, 2021, to site closure) HyunCheol Chung (August 21, 2019, to July 28, 2021)	Severance Hospital Institutional Review Board 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 03722, Korea	4-2019-0438
082006	Young-Iee Park	National Cancer Center Institutional Review Board, 323 Ilsan-ro (809 Madu-1-dong), Ilsandong-gu, Goyang-si Gyeonggi-do, Korea, 10408	NCC2019-0163
082013	Do-Youn Oh (January 30, 2020, to site closure) Yung-Jue Bang (April 2, 2019, to January 30, 2020)	Seoul National University Hospital Institutional Review Board, 101, Daehak-ro, Jongno-gu, Seoul, 03080, Korea	H-1811-042-986

Site No.	Principal investigator name	Name/Address of ethics committee	Approval number
082020	Byoung Yong Shim	The Catholic University of Korea, St. Vincent Hospital Institutional Review Board, 93, Jungbu-daero, Paldal-gu, Suwon-si, Gyeonggi-do, 16247, Korea	VC19MDGT0119
082025	In Gyu Hwang	Chung-Ang University Hospital, 102, Heukseok-ro, Dongjak-gu, Seoul, 06973, Korea	1960-002-372
082026	Hyun Woo Lee	Ajou University Hospital Institutional Review Board 164, World cup-ro, Yeongtong-gu, Suwon-si,Gyeonggi-do, 16499, Korea	AJIRB-MED-CT3-19-192
082031	Keun Wook Lee	Seoul National University Bundang Hospital Institutional Review Board, 7th floor, 821-dong, 173, Gumi-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, 463-707	B-1901/517-401
082032	Min-Hee Ryu (November 8, 2023, to site closure) Yoon-Koo Kang (May 27, 2019, to November 8, 2023)	Asan Medical Center Institutional Review Board, 88 Olympic-ro, 43-gil, Songpa-gu, Seoul, 05505, Korea	2018-1415
082034	Ik Joo Chung	Chonnam National University Hwasun Hospital Institutional Review Board, Institutional Review Board, Chonnam	CNUHH-2018-170

Site No.	Principal investigator name	Name/Address of ethics committee	Approval number
		National University Hwasun Hospital, 160, Ilsim-ri, Hwasun-eup, Hwasun-gun, Jeollanam-do, 519-809, Korea	
082036	Jong Gwang Kim	Kyungpook National University Chilgok Hospital Institutional Review Board, 807, Hoguk-ro, Buk-gu, Daegu, 41404, Korea	KNUCH 2019-05-021-001
086001	Lin Shen	Medical Ethics Committee of Beijing Cancer Hospital, No. 81 Fucheng Road, Haidian District, Beijing, China	2018YW39
086005	Dong Ma	Ethics Committee of Guangdong People`s Hospital, 23F, Haiyin Center, No 98 Donghua South Road, Yuexiu District, Guangzhou, Guangdong Province, China	2018-44-1
086006	Jufeng Wang	Ethics Committee of Henan Cancer Hospital, No.127 Dongming Road, Jinshui District, Zhengzhou, Henan Province, China.	2018106, 23Aug2028
086009	Chunmei Bai	Drug Clinical Trail Ethics Committee of Peking Union Medical College Hospital, No.41 Damucang Hutong, Xicheng District, Beijing, China	HS2018108
086012	Jiuwei Cui	Ethics Committee of The First Hospital of Jilin University,	18Y107-001

Site No.	Principal investigator name	Name/Address of ethics committee	Approval number
		No.71 Xinmin Street, Changchun, Jilin, China	
086021	Yang Yang (March 26, 2019, to site closure) Baorui Li (January 31, 2019, to March 26, 2019)	Ethics Committee of Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School, No. 321 Zhongshan Road, Gulou District, Nanjing, Jiangsu Province, China	2018-145-01
086022	Yuxian Bai	The Ethics Committee of Harbin Medical University Cancer Hospital, No.150 Haping Road, Nangang District, Harbin, Heilongjiang, China	2018-131, 17Oct2018
086024	Ruixing Zhang	Medical Ethics Committee of The Fourth Hospital of Hebei Medical University, No.12 Jiankang Road, Shijiazhuang City, Hebei Province, China	2018131, 4Jan2019
086027	Haijun Zhong	Ethics Committee of Zhejiang Cancer Hospital, 1 Banshan Dong Lu, Gongshu District, Hangzhou City, Zhejiang Province, China	IRB-[2018]438
086030	Rongsheng Zheng	Clinical Medical Research Ethics Committee of the First Affiliated Hospital of Bengbu Medical College, 287 Changhuai Road, Longzihu District, Bengbu City, Anhui Province	[2018]057

Site No.	Principal investigator name	Name/Address of ethics committee	Approval number
086031	Zhendong Chen	Ethics Committee of The Second Hospital of Anhui Medical University, No. 678 Furong Road, Jingkai District, Hefei, Anhui Province, China	YW2018-033(F1)
086032	Tianshu Liu	Ethics Committee of Zhongshan Hospital Fudan University, No.180 Fenglin Road, Xuhui District Shanghai, 200032, China	2018-113
086036	Zengqing Guo	Ethics Committee of Fujian Cancer Hospital, 420 Fumu Road, Jin 'an District, Fuzhou City, Fujian Province, China	2018-038-01
086037	Anwen Liu	Clinical Trial Ethic Committee of The Second Affiliated Hospital of Nanchang University, No.1 Minde Road, Nanchang City, Jiangxi Province, China 330006	[2018] No.14
086038	Hongming Pan	Ethics Committee of Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, 9th Floor, Building 4, 3 Qingchun East Road, Shangcheng District, Hangzhou City, Zhejiang Province, China	20181016-4
086040	Tao Zhang	Clinical Trial Ethic Committee of Huazhong University of Science and Technology, No.1277, Jiefang Avenue,	[2018] No.135

Site No.	Principal investigator name	Name/Address of ethics committee	Approval number
		Jianghan District, Wuhan, China	
086042	Weiwei Shi	Ethics Committee of Chinese PLA General Hospital, No.28 Fuxing Road Beijing, 100853, China	C2018-035-01
086044	Lin Yang	Ethics Committee of Cancer Hospital Chinese Academy of Medical Sciences, NO.17 Panjiayuan Nanli, Chaoyang District, Beijing, China	18-122/1700
086047	Xiaochun Zhang	Medical Ethics Committee of the Affiliated Hospital of Qingdao University, No.16 Jiangsu Road., Qingdao, 266000, China	QYFYEC 2018-053-01
086048	Yi Ba	Ethics Committee of Tianjin Medical University Cancer Institute & Hospital, West Huan-Hu Rd, Ti Yuan Bei, Hexi District, Tianjin, 300060, China	E2018155
086049	Xianli Yin	Ethics Committee of Hunan Cancer Hospital, No.283 Tongzipo Road, Yuelu District, Changsha City, Hunan Province, China	2018 Drug No. [222]
086050	Liwen Ma	Ethics Committee Peking University Third Hospital, 6 / F, Great Wall Computer Building, Huayuan North Road, Haidian District, Beijing, China	(2018)DrugNo. 064-01)

Site No.	Principal investigator name	Name/Address of ethics committee	Approval number
086052	Ruihua Xu	Ethics Committee of Sun Yat-sen University Cancer Center, Room 315, Cuiyuan Building, 23 Xianlie South Road, Guangzhou City, Guangdong Province, China	A2018-015-01
086054	Xi Shi	Ethics Committee of The First Affiliated Hospital of Fujian Medical University, 11th floor, Outpatient Building, 20 Chazhong Road, Fuzhou City, Fujian Province, China	LY2018-016-01
086055	Sheng Hu	Ethics Committee of Hubei Cancer Hospital, 116 Zhuodaoquan South Road, Hongshan District, Wuhan City, Hubei Province, China	[2018] No.26
086060	Ping Gan	Ethics Committee of Yunnan Cancer Hospital, No. 519 Kunzhou Road, Xishan District, Kunming, Yunnan Province, China	YW201827-27Aug2018
086072	Yunpeng Liu	Ethics Committee of The First Hospital of China Medical University, No.155 of Nanjing North Street, Heping District, and No.210 of Baita First Street, Hunnan District Shenyang City, Liaoning Province, China	2018YL035

Site No.	Principal investigator name	Name/Address of ethics committee	Approval number
086074	Jianhua Shi	Ethics Committee of Linyi Cancer Hospital, Intersection of Zhicheng Road and Zhongsheng Street, Hedong District, Linyi, Shandong Province, China, 276034	XY1825
086075	Jingdong Zhang	Ethics Committee of Liaoning Cancer Hospital, No.44 of Xiaoheyan Road, Dadong District, Shenyang City, Liaoning Province, China	20180754
086077	Hong Shen	Human Research Ethics Committee, The Second Affiliated Hospital of Zhejiang University School of Medicine, 88 Jiefang Road, Hangzhou City, Zhejiang Province, China	(2018) Drug No. (534)
086078	Shan Zeng	Ethics Committee of Xiangya Hospital Central South University, No.87 Xiangya Road, Kaifu District, Changsha City, Hunan Province, China	No. 201812161
086080	Jun Zhang	Ethics Committee of Drug Clinical Trials of Ruijin Hospital Shanghai Jiaotong University School of Medicine, No.197 Ruijin Second Road, Huangpu District, Shanghai, China	(2018) No. (81) -3
086083	Lei Yang	Ethics Committee of Nantong Tumor Hospital, No.48 Qingnian West Road,	[2018-009], 7Sep2018

Site No.	Principal investigator name	Name/Address of ethics committee	Approval number
		Chongchuan District, Nantong, 226000, China	
086086	Yulong Zheng	Clinical Research Ethics Committee, The First Affiliated Hospital of Zhejiang University School of Medicine, 79 Qingchun Road, Hangzhou 310003, Zhejiang Province, China	(2018) No. (268）
086089	Lin Wang	Ethics Committee of Hainan General Hospital, No.19 Xiuhua Road, Xiuying District, Haikou, Hainan, China, 570311.	[2018] No.72
086102	Changzheng Li	Medical Ethics Committee of Shandong First Medical University Affiliated Cancer Hospital, No.440 Jiyan Road Jinan, Shandong, China	SDZLEC2018-052-01
086103	Yanru Qin	Scientific Research and Clinical Trial Ethics Committee of The First Affiliated Hospital of Zhengzhou University, NO.1 East Jianshe Road, Erqi District, Zhengzhou City, Henan Province, China	Drug-2018-119
086113	Bangwei Cao	Bioethics Committee, Beijing Friendship Hospital, Capital Medical University, 95 Yong 'an Road, Xicheng District, Beijing, 602, Unit 2, Physical Examination Center, Beijing	2018-P1-Drug 021-01

Site No.	Principal investigator name	Name/Address of ethics committee	Approval number
		Friendship Hospital, 92 Yong 'an Road, Xicheng District, Beijing, China	
086115	Yifu He	Ethics Committee of Anhui Provincial Cancer Hospital, No.107 Huanhudong Road, Hefei, Anhui Province, China	2018-EC comments-19-01
086124	Dong Wang	Ethics Committee of Army Specialty Medical Center of the Chinese People's Liberation Army, No.10 Changjiang Road, Daping, Yuzhong District, Chongqing, China	Drug (2018) No. 03
086127	Diansheng Zhong	Ethics Committee of Tianjin Medical University General Hospital,154 Anshan Road, Heping District, Tianjin, China	IRB2018-055-01
086144	Mafei Kang	Ethics Committee of Affiliated Hospital of Guilin Medical University, No. 15 Lequn Road, Xiufeng District, Guilin, Guangxi Province, China	No. (F2019009)
086150	Zhendong Zheng	Ethics Committee of Northern Theater Command of Chinese People's Liberation Army, No.83 Wenhua Road, Shenhe District, Shenyang City, Liaoning Province, China	No. (2018) 15
086151	Leizhen Zheng	Ethics Committee of Xinhua Hospital Affiliated to Shanghai Jiaotong University School of	XHEC-A-2018-005-1

Site No.	Principal investigator name	Name/Address of ethics committee	Approval number
		Medicine, No.1665, Kongjiang Road, Yangpu District, Shanghai, China	
086152	Ruilian Xu	Ethics Committee of Shenzhen People's Hospital, No. 1017 Dongmen North Road, Luohu District, Shenzhen.Guangdong Province, China	No. (2018) 72
086153	Qi Li	Medical Ethics Committee of Shanghai General Hospital, 85 Wujin Road, Hongkou District, Shanghai, China	No. (2018) 71
086154	Wei Wang	Ethics Committee of The First People's Hospital of Foshan, No.81 North Lingnan Avenue, Foshan, Guangdong, China, 528000.	Drug No. (2018) 12
086155	Xiuling Li	Ethics Committee of Henan Provincial People's Hospital, No.7 Weiwu Road, Jinshui District, Zhengzhou, Henan Province, 450003, China	2018-028-02
086162	Guangyu An	Ethics Committee of Beijing Chao Yang Hospital, No.8 Gongti Nan Road, Chaoyang District, Beijing, China	2018-10-10-2 No.2018-Drug-23
086169	Dong Yan	Ethics Committee Beijing Luhe Hospital, Capital Medical University, Room 322, Building 4, Adult Education Center, 358	2018-LHYW-061-03

Site No.	Principal investigator name	Name/Address of ethics committee	Approval number
		Yudaihe East Street, Tongzhou District, Beijing, China	
086206	Qinghong Guo	Ethics Committee of The First Hospital Of Lanzhou University, No.1 Donggang West Road Lanzhou, 730000, China	2019 No.(20)号, 12Jun2019
090001	Ali Murat Tatli (February 11, 2022, to site closure) Hasan Senol Coskun (August 20, 2019, to February 11, 2022)	Malatya Clinical Trials Ethics Committee, Inonu Universitesi Merkez Kampusu, 44280, Malatya, Turkey	2018/155 dd 14Nov2018
090002	Umut Disel	Malatya Clinical Trials Ethics Committee, Inonu Universitesi Merkez Kampusu, 44280, Malatya, Turkey	2018/155 dd 14Nov2018
090003	Hakan Harputluoglu	Malatya Clinical Trials Ethics Committee, Inonu Universitesi Merkez Kampusu, 44280, Malatya, Turkey	2018/155 dd 14Nov2018
090004	Ozturk Ates (November 4, 2022, to site closure) Berna Oksuzoglu (November 8, 2019, to November 4, 2022)	Malatya Clinical Trials Ethics Committee, Inonu Universitesi Merkez Kampusu, 44280, Malatya, Turkey	2018/155 dd 14Nov2018

Site No.	Principal investigator name	Name/Address of ethics committee	Approval number
787001	Marcia Cruz-Correa	Copernicus Group IRB, 5000 CentreGreen Way, Cary, NC 27513 (part of WIRB)	20182456
886001	Jawyuan Wang	Institutional Review Board Kaohsiung Medical University Chung-Ho Memorial Hospital, No. 100, Tzyou 1st Road, Kaohsiung 807, Taiwan	NA - IRB does not issue an approval number.
886042	Chiajui Yen	Institutional Review Board National Cheng Kung University Hospital, No 138, Sheng-Li Road, Tainan 704, Taiwan	NA - IRB does not issue an approval number.
886045	Yi-Ping Hung (November 3, 2022, to site closure) Yee Chao (May 8, 2019, to November 3, 2022)	Institutional Review Board Taipei Veterans General Hospital, No. 201, Sec. 2, Shih-Pai Road, Taipei 11217, Taiwan	No.1084900050

Fig. S1 Trial profile.



ITT intent-to-treat.

Fig. S2 Post hoc subgroup analysis of objective response rate in the ITT population.



Any subset with fewer than 10 patients would not be shown. The race subcategory "Other" includes not reported, unknown, and other. ORR and odds ratios between arms were calculated using the unstratified Cochran-Mantel-Haenszel method. *CI* confidence interval, *dMMR* mismatch repair-deficient, *ECOG* Eastern Cooperative Oncology Group, *HR* hazard ratio, *ITT* intent-to-treat, *MSI-H/L* microsatellite instability-high/low, *MSS* microsatellite stable, *NE* not estimable, *NR* not reached, *ORR* objective response rate, *PD-L1* programmed death ligand 1, *pMMR* mismatch repair-proficient, *ROW* rest of world, *TAP* Tumor Area Positivity.

Fig. S3 Kaplan-Meier plots of duration of response in a all randomized patients and b the population with TAP score ≥ 5%.



Data cutoff: February 28, 2024.

Fig. S4 Kaplan-Meier plots of duration of response in patients treated with a tislelizumab + chemotherapy and b patients treated with placebo + chemotherapy, who remained progression-free at 3 years versus the ITT population.

A.



B.



Data cutoff: February 28, 2024.

Fig. S5 Least-squares mean change from baseline by treatment arm at **a** cycle 4 **b** and cycle 6.



CI confidence interval, *EMTD* estimated mean treatment difference, *EORTC* European Organisation for Research and Treatment of Cancer, *GHS/QoL* global health status/quality of life, *GI* gastrointestinal, *QLQ-C30* Quality of Life Questionnaire – Core 30, *QLQ-STO22* Quality of Life Questionnaire – Gastric Cancer Module.

Table S1 Subsequent systemic anticancer therapy in the ITT population

Anticancer therapy, *n* (%)	Tislelizumab + chemotherapy (*n* = 501)	Placebo + chemotherapy (*n* = 496)
Any subsequent anticancer systemic therapy	273 (54.5)	300 (60.5)
Chemotherapy	258 (51.5)	286 (57.7)
Targeted therapy	156 (31.1)	165 (33.3)
Immunotherapy	65 (13.0)	98 (19.8)
Other	15 (3.0)	19 (3.8)

Table S2 Prevalence of PD-L1 subgroups by TAP score and CPS

	TAP score, *n* (%) *N* = 997		CPS, *n* (%) *N* = 974	
PD-L1 status TAP score/CPS	Tislelizumab + chemotherapy (*n* = 501)	Placebo + chemotherapy (*n* = 496)	Tislelizumab + chemotherapy (*n* = 491)	Placebo + chemotherapy (*n* = 483)
≥1%/≥1	432 (86.2)	453 (91.3)	420 (85.5)	434 (89.9)
<1%/<1	69 (13.8)	43 (8.7)	71 (14.5)	49 (10.1)
≥5%/≥5	274 (54.7)	272 (54.8)	254 (51.7)	269 (55.7)
<5%/<5	227 (45.3)	224 (45.2)	237 (48.3)	214 (44.3)
≥10%/≥10	136 (27.1)	145 (29.2)	151 (30.8)	138 (28.6)
<10%/<10	365 (72.9)	351 (70.8)	340 (69.2)	345 (71.4)

Response assessed by investigator per Response Evaluation Criteria in Solid Tumors version 1.1. Data cutoff, February 28, 2023. PD-L1 TAP score was determined with the VENTANA PD-L1 (SP263) Assay. *CPS* combined positive score, *PD-L1* programmed death ligand 1, *TAP* Tumor Area Positivity.

Table S3 Response in the all randomized population and the population with PD-L1 TAP Score ⩾ 5%[a]

	All randomized patients		**Population with PD-L1 TAP score ≥ 5%**	
	Tislelizumab + chemotherapy (*n* = 501)	**Placebo + chemotherapy (*n* = 496)**	**Tislelizumab + chemotherapy (*n* = 274)**	**Placebo + chemotherapy (*n* = 272)**
Confirmed objective response rate, *n* [% (95% CI)]	237 [47.3 (42.9–51.8)]	201 [40.5 (36.2–45.0)]	141 [51.5 (45.4–57.5)]	116 [42.6 (36.7–48.8)]
Odds ratio (95% CI)[b]	1.33 (1.03–1.72)		1.45 (1.03–2.04)	
Best overall response, *n* (%)				
CR	19 (3.8)	19 (3.8)	12 (4.4)	7 (2.6)
PR	218 (43.5)	182 (36.7)	129 (47.1)	109 (40.1)
Stable disease[c]	185 (36.9)	197 (39.7)	90 (32.8)	104 (38.2)
Non-CR/non-PD	28 (5.6)	15 (3.0)	11 (4.0)	6 (2.2)
PD	23 (4.6)	55 (11.1)	11 (4.0)	32 (11.8)
Undetermined[d]	28 (5.6)	28 (5.6)	21 (7.7)	14 (5.1)
Disease control rate, *n* [% (95% CI)]	450 [89.8 (86.8–92.3)]	413 [83.3 (79.7–86.4)]	242 [88.3 (83.9–91.9)]	226 [83.1 (78.1–87.3)]
Clinical benefit rate, *n* [% (95% CI)]	316 [63.1 (58.7–67.3)]	292 [58.9 (54.4–63.2)]	178 [65.0 (59.0–70.6)]	161 [59.2 (53.1–65.1)]
Median duration of response (95% CI), months[e]	8.6 (7.9–11.1)	7.2 (6.0–8.5)	10.0 (8.2–16.8)	6.9 (5.7–8.5)
Median time to response (range), months[e]	1.4 (0.9–13.4)	1.4 (1.0–17.5)	1.4 (0.9–11.3)	1.4 (1.0–17.5)

Response assessed by investigator per Response Evaluation Criteria in Solid Tumors version 1.1. [a]Data cutoff, February 28, 2024. [b]Cochran-Mantel-Haenszel test stratified by region (East Asia vs. other regions), PD-L1 expression (all randomized patients only), and

presence of peritoneal metastasis. [c]Stable disease includes patients with non-CR/non-progressive disease. [d]Undetermined includes patients with non-evaluable or non-assessable responses. [e]Among patients who achieved a confirmed CR or PR only. *CI* confidence interval, *CR* complete response, *PD* progressive disease, *PD-L1* programmed death ligand 1, *PR* partial response, *TAP* Tumor Area Positivity.

Table S4 Baseline characteristics of patients who remained progression-free at 3 years

Characteristics	Tislelizumab + chemotherapy (*n* = 50)	Placebo + chemotherapy (*n* = 20)	Total (*N* = 70)
Time from initial cancer diagnosis to study entry, months[a]			
Median (IQR)	2.5 (1.1–29.0)	2.0 (1.2–15.5)	2.1 (1.1–27.1)
Metastatic disease[b]	48 (96.0)	20 (100.0)	68 (97.1)
Primary location, *n* (%)			
Gastroesophageal junction	5 (10.0)	4 (20.0)	9 (12.9)
Stomach	45 (90.0)	16 (80.0)	61 (87.1)
No. of metastatic sites at study entry, *n* (%)[c,d]			
0-2	41 (82.0)	15 (75.0)	56 (80.0)
≥ 3	9 (18.0)	4 (20.0)	13 (18.6)
Liver metastases, *n* (%)			
Yes	18 (36.0)	9 (45.0)	27 (38.6)
No	32 (64.0)	11 (55.0)	43 (61.4)
Presence of peritoneal metastasis, *n* (%)[d]			
Yes	13 (26.0)	4 (20.0)	17 (24.3)
No	37 (74.0)	16 (80.0)	53 (75.7)
Histologic grade, *n* (%)[d]			
Gx - Grade cannot be assessed	9 (18.0)	0	9 (12.9)
G1 - Well differentiated	2 (4.0)	3 (15.0)	5 (7.1)
G2 - Moderately differentiated	15 (30.0)	9 (45.0)	24 (34.3)
G3 - Poorly differentiated	24 (48.0)	8 (40.0)	32 (45.7)
PD-L1 expression, *n* (%)			
PD-L1 score < 5%	17 (34.0)	8 (40.0)	25 (35.7)
PD-L1 score ≥ 5%	33 (66.0)	12 (60.0)	45 (64.3)
MSI or MMR status, n (%)			
MSI-H/dMMR	4 (8.0)	1 (5.0)	5 (7.1)
MSI-L/MSS/pMMR	42 (84.0)	16 (80.0)	58 (82.9)
Unknown	4 (8.0)	3 (15.0)	7 (10.0)

[a]Study entry date was referred to randomization date. [b]Disease stage rating at screening was based on American Joint Committee on Cancer TNM Staging Classification for Carcinoma of the Stomach and for Carcinoma of the Esophagus and Esophagogastric Junction (8th ed.,

2017). [c]One patient in the placebo + chemotherapy treatment arm had metastatic site removed by surgery before study entry. [d]Denotes statistical significance ($p < 0.05$) for patients in ITT versus those who remained progression free at 3 years. *dMMR* mismatch repair-deficient, *G* grade, *ITT* intent-to-treat, *IQR* interquartile range, *MMR* mismatch repair, *MMS* microsatellite stable, *MSI-H/L* microsatellite instability-high/low, *PD-L1* programmed death ligand 1, *PFS* progression-free survival, *pMMR* mismatch repair-proficient.

Table S5 Response in patients who remained progression-free at 3 years

	Patients who remained progression free at 3 years	
	Tislelizumab + chemotherapy (*n* = 50)	**Placebo + chemotherapy (*n* = 20)**
Confirmed objective response rate, *n* [% (95% CI)][a]	46 [92.0 (80.8–97.8)]	17 [85.0 (62.1–96.8)]
Odds ratio (95% CI)[a]	1.57 (0.32–7.79)	
Best overall response, No. (%)		
CR	12 (24.0)	6 (30.0)
PR	34 (68.0)	11 (55.0)
SD[b]	2 (4.0)	1 (5.0)
Non-CR/non-PD	2 (4.0)	2 (10.0)
PD	0 (0.0)	0 (0.0)
Disease control rate, *n* [% (95% CI)][a]	50 [100.0 (92.9–100.0)]	20.0 [100.0 (83.2–100.0)]
Clinical benefit rate,[c] *n* [% (95% CI)][a]	50 [100.0 (92.9–100.0)]	20.0 [100.0 (83.2–100.0)]
Median time to response (range), months	1.5 (1.2–13.4)	1.3 (1.2–17.5)

[a]Exact Clopper-Pearson two-sided confidence interval. [b]Stable disease includes patients with non-CR/non-progressive disease. [c]Clinical benefit rate is defined as the proportion of patients who have CR, PR, or SD including non-CR/non-PD of ⩾ 24 weeks in duration. *CI* confidence interval, *CR* complete response, *PD* progressive disease, *PD-L1* programmed death ligand 1, *PFS* progression-free survival, *PR* partial response, *SD* stable disease.

Table S6 Time to deterioration for EORTC QLQ-C30 and QLQ-STO22 scales

		Tislelizumab + chemotherapy (*n* = 501)	**Placebo + chemotherapy (*n* = 496)**
EORTC QLQ-C30 GHS/QoL	Patients worsened, *n* (%)	121 (24.2)	144 (29.0)
	Patients censored, *n* (%)	380 (75.8)	352 (71.0)
	Median time to deterioration (95% CI), months[a]	NR (36.0–NE)	38.0 (26.7–NE)
	Stratified HR (95% CI)[b]	0.77 (0.60–0.98)	
	Stratified log-rank test *p* value[b,c]	0.0168	
Physical functioning	Patients worsened, *n* (%)	124 (24.8)	151 (30.4)
	Patients censored, *n* (%)	377 (75.2)	345 (69.6)
	Median time to deterioration, months (95% CI)[a]	NR (30.4–NE)	37.7 (16.6–NE)
	Stratified HR (95% CI)[b]	0.72 (0.57–0.92)	
	Stratified log-rank test *p* value[b,c]	0.0036	
Fatigue	Patients worsened, *n* (%)	193 (38.5)	209 (42.1)
	Patients censored, *n* (%)	308 (61.5)	287 (57.9)
	Median time to deterioration (95% CI), months[a]	16.9 (9.8–NE)	9.4 (5.4–17.8)
	Stratified HR (95% CI)[b]	0.83 (0.68–1.01)	
	Stratified log-rank test *p* value[b,c]	0.0310	
EORTC QLQ-STO22 Symptom index	Patients worsened, *n* (%)	50 (10.0)	72 (14.5)
	Patients censored, *n* (%)	451 (90.0)	424 (85.5)
	Median time to deterioration (95% CI), months[a]	NR (NE–NE)	NR (NE–NE)
	Stratified HR (95% CI)[b]	0.64 (0.45–0.92)	
	Stratified log-rank test *p* value[b,c]	0.0080	
Dysphagia/ odynophagia	Patients worsened, *n* (%)	48 (9.6)	54 (10.9)
	Patients censored, *n* (%)	453 (90.4)	442 (89.1)
	Median time to deterioration (95% CI), months[a]	NR (NE–NE)	NR (NE-NE)
	Stratified HR (95% CI)[b]	0.81 (0.54–1.19)	
	Stratified log-rank test *p* value[b,c]	0.1387	
Pain/discomfort	Patients worsened, *n* (%)	110 (22.0)	134 (27.0)
	Patients censored, *n* (%)	391 (78.0)	362 (73.0)
	Median time to deterioration (95% CI), months[a]	NR (28.3–NE)	42.2 (33.1–NE)
	Stratified HR (95% CI)[b]	0.74 (0.58–0.96)	
	Stratified log-rank test *p* value[b,c]	0.0109	

Upper gastrointestinal symptoms	Patients worsened, *n* (%)	101 (20.2)	127 (25.6)
	Patients censored, *n* (%)	400 (79.8)	369 (74.4)
	Median time to deterioration (95% CI), months[a]	NR (NE-NE)	NR (NE–NE)
	Stratified HR (95% CI)[b]	0.73 (0.56–0.95)	
	Stratified log-rank test *p* value[c,d]	0.0085	
Dietary restrictions	Patients worsened, *n* (%)	100 (20.0)	99 (20.0)
	Patients censored, *n* (%)	401 (80.0)	397 (80.0)
	Median time to deterioration (95% CI), months[a]	NR (40.3–NE)	NR (NE–NE)
	Stratified HR (95% CI)[b]	0.96 (0.73–1.27)	
	Stratified log-rank test *p* value[c,d]	0.3936	

Percentages were based on *N*. [a]Estimates are based on Kaplan-Meier method. [b]Stratified by regions (East Asia vs. rest of the world), PD-L1 expression, and presence of peritoneal metastasis.[c]One-sided *p* value was estimated from stratified log-rank test. *CI* confidence interval, EORTC, European Organisation for Research and Treatment of Cancer, *GHS/QoL* global health status/quality of life, *HR* hazard ratio, *NE* not estimable, *NR* not reached, *PD-L1* programmed death ligand 1, *QLQ-C30* Quality of Life Questionnaire – Core 30, *QLQ-STO22* Quality of Life Questionnaire – Stomach.

Table S7 Summary of safety outcomes

Events, *n* (%)[a]	Tislelizumab + chemotherapy (*n* = 498)	Placebo + chemotherapy (*n* = 494)
Any treatment-related adverse event	483 (97.0)	476 (96.4)
Grade ≥ 3 treatment-related adverse event	269 (54.0)	246 (49.8)
Serious treatment-related adverse events	113 (22.7)	72 (14.6)
Treatment-related adverse events leading to discontinuation	83 (16.7)	40 (8.1)
Treatment-emergent adverse events leading to dose modification of tislelizumab or placebo	246 (49.4)	240 (48.6)
Treatment-related adverse events leading to death[b]	6 (1.2)	2 (< 1)
Any immune-mediated adverse event[c,d]	157 (31.5)	58 (11.7)
Grade ≥ 3 immune-mediated adverse event	38 (7.6)	10 (2.0)
Serious immune-mediated adverse events	37 (7.4)	9 (1.8)
Immune-mediated adverse events leading to discontinuation	22 (4.4)	1 (0.2)
Immune-mediated adverse events leading to dose modification of tislelizumab or placebo	34 (6.8)	9 (1.8)
Immune-mediated adverse events leading to death	1 (0.2)	0
Immune-mediated adverse events treated with corticosteroids	42 (8.4)	12 (2.4)

[a]Adverse events terms are coded using Medical Dictionary for Regulatory Activities version 24.0. [b]Excludes death due to disease under study. [c]Immune-mediated adverse events are identified based on Immune-Mediated Adverse Events Company Custom Queries v2.2. [d]Immune-mediated adverse events are identified from all adverse events that had an onset date or a worsening in severity from baseline (pretreatment) on or after the first dose of study drug and up to 90 days from the last dose of study drug, regardless of whether the patient started a new anticancer therapy.

Table S8 Summary of safety outcomes in patients who remained progression-free at 3 years

Events, *n* (%)[a]	Tislelizumab + chemotherapy (*n* = 50)	Placebo + chemotherapy (*n* = 20)
Any treatment-related adverse event	50 (100.0)	20 (100.0)
Grade ≥ 3 treatment-related adverse event	31 (62.0)	12 (60.0)
Serious treatment-related adverse events	10 (20.0)	4 (20.0)
Treatment-related adverse events leading to discontinuation	14 (28.0)	2 (10.0)
Treatment-emergent adverse events leading to dose modification of tislelizumab or placebo	37 (74.0)	17 (85.0)
Treatment-related adverse events leading to death	0 (0.0)	0 (0.0)

[a]Adverse events terms are coded using Medical Dictionary for Regulatory Activities version 24.0.

Table S9 Summary of immune-mediated adverse events in the safety population

Events, *n* (%)	Tislelizumab + chemotherapy (*n* = 498)	Placebo + chemotherapy (*n* = 494)
Any immune-mediated adverse event	157 (31.5)	58 (11.7)
Hypothyroidism	64 (12.9)	16 (3.2)
Skin reaction	55 (11.0)	15 (3.0)
Pneumonitis	19 (3.8)	2 (0.4)
Hyperthyroidism	16 (3.2)	4 (0.8)
Hepatitis	10 (2.0)	2 (0.4)
Diabetes mellitus	8 (1.6)	1 (0.2)
Colitis	6 (1.2)	10 (2.0)
Musculoskeletal	5 (1.0)	0
Myocarditis/pericarditis	4 (0.8)	1 (0.2)
Thyroiditis	3 (0.6)	3 (0.6)
Adrenal insufficiency	3 (0.6)	2 (0.4)
Myositis/rhabdomyolysis	3 (0.6)	2 (0.4)
Hypophysitis	3 (0.6)	1 (0.2)
Nephritis and renal dysfunction	3 (0.6)	0
Pancreatitis	2 (0.4)	1 (0.2)
Central nervous system	1 (0.2)	0
Blood dyscrasias	1 (0.2)	0
Other	2 (0.4)	5 (1.0)

Immune-mediated adverse events are identified based on Immune-Mediated Adverse Events Company Custom Queries v2.2. Immune-mediated adverse events are identified from all adverse events that had an onset date or a worsening in severity from baseline (pretreatment) on or after the first dose of study drug and up to 90 days from the last dose of study drug, regardless of whether the patient started a new anticancer therapy.